scholarly journals Progeroid and marfanoid aspect-lipodystrophy syndrome

2020 ◽  
Author(s):  
Keyword(s):  
Lipodystrophy Syndrome

How to diagnose a lipodystrophy syndrome

2012 ◽  
Vol 73 (3) ◽  
pp. 170-189 ◽  
Author(s):  
Marie-Christine Vantyghem ◽  
Anne-Sophie Balavoine ◽  
Claire Douillard ◽  
Frédérique Defrance ◽  
Lucile Dieudonne ◽  
...  
Keyword(s):  
Lipodystrophy Syndrome

scholarly journals Markedly Diminished Lipolysis and Partial Restoration of Glucose Metabolism, without Changes in Fat Distribution after Extended Discontinuation of Protease Inhibitors in Severe Lipodystrophic Human Immunodeficient Virus-1-Infected Patients

2004 ◽  
Vol 89 (7) ◽  
pp. 3554-3560 ◽  
Author(s):  
Marc van der Valk ◽  
Gideon Allick ◽  
Gerrit Jan Weverling ◽  
Johannes A. Romijn ◽  
Mariette T. Ackermans ◽  
...  
Keyword(s):  
Glucose Production ◽  
Fat Distribution ◽  
Dual Energy ◽  
Glucose Disposal ◽  
Computed Tomography Scan ◽  
X Ray ◽  
Lipodystrophy Syndrome ◽  
Total Glucose ◽  
Tomography Scan ◽  
Hiv 1

Abstract Treatment for HIV-1 infection is often complicated by a lipodystrophy syndrome associated with insulin resistance and an elevated rate of lipolysis. In eight HIV-1 infected men with lipodystrophy syndrome, we studied the effects of replacement of protease inhibitor (PI) by abacavir on insulin sensitivity and lipolysis by hyperinsulinemic euglycemic clamp and on fat distribution assessed by dual-energy x-ray absorptiometry and computed tomography scan. Glucose metabolism and lipolysis were assessed by tracer dilution employing [6,6-2H2]glucose and [2H5]glycerol, respectively. Data are expressed as mean ± sd or 95% confidence interval (CI), as appropriate. There were no significant changes in fat distribution assessed by dual-energy x-ray absorptiometry and computed tomography scan at wk 36 and wk 96. The fasting total glucose production decreased from 16.1 ± 2.5 at study entry by 1.1 (range, −2.1 to −0.1) to 15.0 ± 1.5 μmol/kg·min after PI withdrawal at wk 36 (n = 8). In an analysis restricted to the patients on treatment at wk 96 (n = 6), the decrease was 0.9 (range, −2.1 to 0.3) μmol/kg·min. During insulin infusion, glucose oxidation (as percent of total glucose disposal) increased from 36.8 ± 12.7% by 11.0% (range, 1.3–20.8) to 47.9 ± 13.9% in the wk 36 analysis. In the analysis restricted to the patients on treatment at wk 96 (n = 6) the increase was 7.7 (−4.0 to 19.4)%. Fasting lipolysis decreased from 2.7 ± 0.6 μmol/kg·min by 0.9 (−1.6 to −0.2) to 1.8 ± 0.3 μmol/kg·min in the wk-96 analysis (n = 6). The replacement of the studied PIs by abacavir in severe lipodystrophic HIV-1-infected patients results in a marked reduction of lipolysis. In contrast, fasting glucose production and insulin-stimulated glucose oxidation improve moderately, whereas insulin-stimulated glucose disposal and fat distribution do not change.

Lipodystrophy syndrome in HIV treatment-multiexperienced patients: implication of resistin

2014 ◽  
Vol 37 (6) ◽  
pp. 533-539 ◽  
Author(s):  
V. Arama ◽  
D. I. Munteanu ◽  
A. Streinu Cercel ◽  
D. A. Ion ◽  
R. Mihailescu ◽  
...  
Keyword(s):  
Hiv Treatment ◽  
Lipodystrophy Syndrome

scholarly journals Lipodystrophy syndrome in HIV-infected children on HAART

2009 ◽  
Vol 10 (4) ◽  
pp. 76 ◽  
Author(s):  
Steve Innes ◽  
Leon Levin ◽  
Mark Cotton
Keyword(s):  
Clinical Practice ◽  
Early Detection ◽  
Nucleoside Reverse Transcriptase Inhibitor ◽  
Fat Distribution ◽  
Transcriptase Inhibitor ◽  
Routine Clinical Practice ◽  
Lipodystrophy Syndrome ◽  
Practical Guidelines ◽  
Reverse Transcriptase Inhibitor

Lipodystrophy Syndrome (LD) is common in HIV-infected children, particularly in those taking Didanosine, Stavudine, or Zidovudine. Lipoatrophy in particular causes major stigmatization and interferes with adherence. In addition, LD may have significant long-term health consequences, particularly cardiovascular. Since the stigmatizing fat distribution changes of LD are largely permanent, the focus of management remains on early detection and arresting progression. Practical guidelines for surveillance and avoidance of LD in routine clinical practice are presented. Diagnosis of LD is described and therapeutic options are reviewed. The most important therapeutic intervention is to switch the most likely offending antiretroviral to a non-LD-inducing agent as soon as LD is recognised. Typically, where lipoatrophy or lipohypertrophy is diagnosed, the thymidine nucleoside reverse transcriptase inhibitor (NRTI) is switched to a non-thymidine agent such as Abacavir (or Tenofovir in adults). Where dyslipidaemia is predominant, a dietician review is helpful, and the clinician may consider switching to a protease inhibitor (PI)-sparing regimen or to Atazanavir.

scholarly journals HIV/antiretroviral therapy–related lipodystrophy syndrome (HALS) is associated with higher RBP4 and lower omentin in plasma

2015 ◽  
Vol 21 (7) ◽  
pp. 711.e1-711.e8 ◽  
Author(s):  
J. Peraire ◽  
M. López-Dupla ◽  
V. Alba ◽  
R. Beltrán-Debón ◽  
E. Martinez ◽  
...  
Keyword(s):  
Antiretroviral Therapy ◽  
Lipodystrophy Syndrome ◽  
Hiv Antiretroviral Therapy

scholarly journals Antiretroviral therapy and genetic predisposition: Cofactors contributing to the lipodystrophy syndrome

2014 ◽  
Vol 6 (7) ◽  
pp. 138-147
Author(s):  
D. Mahajan Supriya ◽  
Tripathy Srikanth ◽  
Bhattacharya Jayanta ◽  
Gaikwad Asmita ◽  
Pawar Jyoti ◽  
...  
Keyword(s):  
Antiretroviral Therapy ◽  
Genetic Predisposition ◽  
Lipodystrophy Syndrome

Increased systemic and adipose tissue cytokines in patients with HIV-associated lipodystrophy

2004 ◽  
Vol 286 (2) ◽  
pp. E261-E271 ◽  
Author(s):  
Julia A. Johnson ◽  
Jeanine B. Albu ◽  
Ellen S. Engelson ◽  
Susan K. Fried ◽  
Yoritaro Inada ◽  
...  
Keyword(s):  
Adipose Tissue ◽  
Highly Active Antiretroviral Therapy ◽  
Proinflammatory Cytokine ◽  
Whole Body ◽  
Metabolic Abnormalities ◽  
Lipodystrophy Syndrome ◽  
Highly Active ◽  
Tnf Α ◽  
Adipose Tissue Remodeling ◽  
Hiv Lipodystrophy

The lipodystrophy syndrome (adipose tissue redistribution and metabolic abnormalities) observed with highly active antiretroviral therapy (HAART) during human immunodeficiency virus (HIV) infection may be related to increased proinflammatory cytokine activity. We measured acute cytokine (TNF-α, IL-6, leptin), glycerol, and lactate secretion from abdominal subcutaneous adipose tissue (SAT), and systemic cytokine levels, in HIV-infected subjects with and without lipodystrophy (HIVL+ and HIVL–, respectively) and healthy non-HIV controls. Lipodystrophy was confirmed and characterized as adipose tissue redistribution in HIVL+ compared with HIVL– and controls, by dual-energy X-ray absorptiometry and by whole body MRI. TNF-α secretion from abdominal SAT and circulating levels of IL-6, soluble TNF receptors I and II, and insulin were elevated in HIVL+ relative to HIVL– and/or controls, particularly in HIVL+ undergoing HAART. In the HIV-infected group as a whole, IL-6 secretion from abdominal SAT and serum IL-6 were positively associated with visceral fat and were negatively associated with the relative amount of lower limb adipose tissue ( P < 0.01). Decreased leptin and increased lactate secretion from abdominal SAT were specifically associated with HAART. In conclusion, increased cytokine secretion from adipose tissue and increased systemic proinflammatory cytokine activity may play a significant role in the adipose tissue remodeling and/or the metabolic abnormalities associated with the HIV-lipodystrophy syndrome in patients undergoing HAART.

Sign in / Sign up

Export Citation Format

Share Document